Terns Pharmaceuticals, Inc. ( (TERN) ) has released its Q3 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Terns Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing innovative treatments for chronic myeloid leukemia (CML) and other cancers. The company is known for its lead program, TERN-701, a selective allosteric BCR-ABL inhibitor with a promising efficacy and safety profile.
In its third-quarter 2025 earnings report, Terns Pharmaceuticals highlighted significant progress in its oncology pipeline, particularly with TERN-701, which showed unprecedented efficacy data in a Phase 1 trial for CML. The company also announced that its cash reserves are expected to sustain operations into 2028.
Key financial metrics from the report include a net loss of $24.6 million for the quarter, an increase from the previous year, alongside a rise in research and development expenses to $19.9 million. The company also reported a decrease in general and administrative expenses, reflecting a strategic focus on its core oncology programs.
Terns Pharmaceuticals is shifting its focus exclusively to oncology, discontinuing internal development of its metabolic programs. The company is actively seeking strategic partnerships to advance its remaining metabolic assets, including TERN-501 and TERN-801.
Looking ahead, Terns Pharmaceuticals remains committed to advancing its oncology pipeline, with upcoming presentations of expanded data from the CARDINAL trial at the ASH Annual Meeting. The company aims to bring its promising therapies to market, enhancing treatment options for patients with CML.